Kezar Life Sciences

Kezar Life Sciences

Kezar Life Sciences is a development-stage biotechnology company focused on developing novel small molecule therapeutics targeting immunoproteasome inhibition for the treatment of autoimmune disorders. KZR-616, Kezar’s lead product candidate, is currently in Phase II proof-of-concept trial in lupus nephritis (LN) on top of current standard of care with a readout expected in 2021. Moreover, further clinical trials have been initiated to evaluate KZR-616 in further autoimmune disorders with high unmet medical need such as warm hemolytic anemia and immune-mediated and  inflammatory myopathies where proteasome inhibitors like Velcade have proven  efficacious but too toxic for chronic treatment.